The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Targeting Persisters for Tuberculosis Control
Open accessAbstract
Mycobacterial persisters, the survivors from antibiotic exposure, necessitate the lengthy treatment of tuberculosis (TB) and pose a significant challenge for our control of the disease. We suggest that persisters in TB are heterogeneous in nature and comprise various proportions of the population depending on the circumstances; the mechanisms of their formation are complex and may be related to those required for persistence in chronic infection. Results from recent studies implicate multiple pathways for persister formation, including energy production, the stringent response, global regulators, the trans -translation pathway, proteasomal protein degradation, toxin-antitoxin modules, and transporter or efflux mechanisms. A combination of specifically persister-targeted approaches, such as catching them when active and susceptible either by stimulating them to “wake up” or by intermittent drug dosing, the development of new drugs, the use of appropriate drug combinations, and combined chemotherapy and immunotherapy, may be needed for more effective elimination of persisters and better treatment of TB. Variations in levels of persister formation and in host genetics can play a role in the outcome of clinical treatment, and thus, these may entail personalized treatment regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 3×
“Besides the wellknown strong synergy between PZA and TMC207 (2, 35), a recent study has shown that adding clofazimine could further enhance the synergy of PZA and TMC207 in mice (72).”
BackgroundThe spectrum of latent tuberculosis: rethinking the biology and intervention strategies
Barry, C. E., Boshoff, H. I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., Schnappinger, D., Wilkinson, R. J., & Young, D. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2236 · Cited by 1,422
Betts, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A., & Duncan, K. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02779.x · Cited by 1,395 · cited 3×
“Microarray analyses have identified a plethora of genes that are upregulated in nongrowing putative persister bacteria in starvation (7) and in the Wayne model, where DosR, a transcription factor, was found to control the expression of the 48-gene DosR regulon (78).”
BackgroundMcKinney, J. D., zu Bentrup, K. H., Muñoz-Elías, E. J., Miczak, A., Chen, B., Chan, W.-T., Swenson, D., Sacchettini, J. C., Jacobs, W. R., & Russell, D. G. (2000) · Nature · doi:10.1038/35021074 · Cited by 1,360
Genetic requirements for mycobacterial survival during infection
Sassetti, C. M., & Rubin, E. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2134250100 · Cited by 1,354
TREATMENT OF STAPHYLOCOCCAL INFECTIONS WITH PENICILLIN BY INTERMITTENT STERILISATION
Bigger, J. (1944) · The Lancet · doi:10.1016/s0140-6736(00)74210-3 · Cited by 1,178
Wayne, L. G., & Hayes, L. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.6.2062-2069.1996 · Cited by 1,141
Mycobacterial persistence requires the utilization of host cholesterol
Pandey, A. K., & Sassetti, C. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711159105 · Cited by 1,064 · cited 2×
“(vi) Elevated transporter activity, such as Mce4, is involved in cholesterol uptake which enriches persisters (59); in addition, a recent study suggested that M.”
BackgroundBistability, Epigenetics, and Bet-Hedging in Bacteria
Veening, J.-W., Smits, W. K., & Kuipers, O. P. (2008) · Annual Review of Microbiology · doi:10.1146/annurev.micro.62.081307.163002 · Cited by 1,018
Toxin-antitoxin loci are highly abundant in free-living but lost from host-associated prokaryotes
Pandey, D. P. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki201 · Cited by 896
Multidrug Tolerance of Biofilms and Persister Cells
Lewis, K. (2008) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-75418-3_6 · Cited by 804
Fox, W., Ellard, G. A., & Mitchison, D. A. (1999) · PubMed · Cited by 797
Muñoz-Elías, E. J., & McKinney, J. D. (2005) · Nature Medicine · doi:10.1038/nm1252 · Cited by 756
Glickman, M. S., Cox, J. S., & Jacobs, W. R. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80250-6 · Cited by 655
Camacho, L. R., Ensergueix, D., Perez, E., Gicquel, B., & Guilhot, C. (1999) · Molecular Microbiology · doi:10.1046/j.1365-2958.1999.01593.x · Cited by 621
The curious characteristics of pyrazinamide: a review.
Zhang, Y., & Mitchison, D. A. (2003) · PubMed · Cited by 586
Self-citationSOS Response Induces Persistence to Fluoroquinolones in Escherichia coli
Dörr, T., Lewis, K., & Vulić, M. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000760 · Cited by 534
Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux Mechanism
Adams, K. N., Takaki, K., Connolly, L. E., Wiedenhoft, H., Winglee, K., Humbert, O., Edelstein, P. H., Cosma, C. L., & Ramakrishnan, L. (2011) · Cell · doi:10.1016/j.cell.2011.02.022 · Cited by 530
Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis
Shi, W., Zhang, X., Jiang, X., Yuan, H., Lee, J. S., Barry, C. E., Wang, H., Zhang, W., & Zhang, Y. (2011) · Science · doi:10.1126/science.1208813 · Cited by 514
Self-citationThe Enduring Hypoxic Response of Mycobacterium tuberculosis
Rustad, T. R., Harrell, M. I., Liao, R., & Sherman, D. R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001502 · Cited by 491
Zhang, Y. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg446 · Cited by 477
Self-citationTherapy of tuberculosis in mice by DNA vaccination
Lowrie, D. B., Tascon, R. E., Bonato, V. L. D., Lima, V. M. F., Faccioli, L. H., Stavropoulos, E., Colston, M. J., Hewinson, R. G., Moelling, K., & Silva, C. L. (1999) · Nature · doi:10.1038/22326 · Cited by 474
Voskuil, M. I., Visconti, K. C., & Schoolnik, G. K. (2004) · Tuberculosis · doi:10.1016/j.tube.2004.02.003 · Cited by 448
Observations on the Mechanism of Action of Penicillin.
Hobby, G. L., Meyer, K., & Chaffee, E. (1942) · Experimental Biology and Medicine · doi:10.3181/00379727-50-13773 · Cited by 444
Deb, C., Lee, C.-M., Dubey, V. S., Daniel, J., Abomoelak, B., Sirakova, T. D., Pawar, S., Rogers, L., & Kolattukudy, P. E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006077 · Cited by 440
Cytological and Transcript Analyses Reveal Fat and Lazy Persister-Like Bacilli in Tuberculous Sputum
Garton, N. J., Waddell, S. J., Sherratt, A. L., Lee, S.-M., Smith, R. J., Senner, C., Hinds, J., Rajakumar, K., Adegbola, R. A., Besra, G. S., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050075 · Cited by 435
Self-citationTHE MAGIC BULLETS AND TUBERCULOSIS DRUG TARGETS
Zhang, Y. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100120 · Cited by 432
Self-citationCharacterization and Transcriptome Analysis of Mycobacterium tuberculosis Persisters
Keren, I., Minami, S., Rubin, E., & Lewis, K. (2011) · mBio · doi:10.1128/mbio.00100-11 · Cited by 404
Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection
Tufariello, J. M., Chan, J., & Flynn, J. L. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00741-2 · Cited by 403
Bacterial Viability and Culturability
Barer, M. R., & Harwood, C. R. (1999) · Advances in Microbial Physiology · doi:10.1016/s0065-2911(08)60166-6 · Cited by 376
Self-citationDahl, J. L., Kraus, C. N., Boshoff, H. I. M., Doan, B., Foley, K., Avarbock, D., Kaplan, G., Mizrahi, V., Rubin, H., & Barry, C. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1631248100 · Cited by 349
Rustomjee, R., Lienhardt, C., Kanyok, T. P., Davies, G., Levin, J., Mthiyane, T., Reddy, C., Sturm, A. W., Sirgel, F. A., Allen, J., et al. (2008) · PubMed · Cited by 326
Is Adipose Tissue a Place for Mycobacterium tuberculosis Persistence?
Neyrolles, O., Hernández-Pando, R., Pietri-Rouxel, F., Fornès, P., Tailleux, L., Payán, J. A. B., Pivert, E., Bordat, Y., Aguilar, D., Prévost, M.-C., et al. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000043 · Cited by 325
Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 Days
Jindani, A., Doré, C. J., & Mitchison, D. A. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200210-1125oc · Cited by 321
Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., O'Brien, R. J., Vernon, A. N., Chaisson, R. E., Bishai, W. R., & Grosset, J. H. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200310-1380oc · Cited by 314
McCune, R. M., Feldmann, F. M., Lambert, H. P., & McDermott, W. (1966) · The Journal of Experimental Medicine · doi:10.1084/jem.123.3.445 · Cited by 310
McCune, R. M., Tompsett, R., & McDermott, W. (1956) · The Journal of Experimental Medicine · doi:10.1084/jem.104.5.763 · Cited by 307
Shi, L., Sohaskey, C. D., Kana, B. D., Dawes, S., North, R. J., Mizrahi, V., & Gennaro, M. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507850102 · Cited by 301
Cho, S. H., Warit, S., Wan, B., Hwang, C. H., Pauli, G. F., & Franzblau, S. G. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00055-06 · Cited by 292
Conde, M. B., Efron, A., Loredo, C., De Souza, G. R. M., Graça, N. P., Cezar, M. C., Ram, M., Chaudhary, M. A., Bishai, W. R., Kritski, A. L., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60333-0 · Cited by 289
Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis
Burman, W. J., Goldberg, S., Johnson, J. L., Muzanye, G., Engle, M., Mosher, A. W., Choudhri, S., Daley, C. L., Munsiff, S. S., Zhao, Z., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200603-360oc · Cited by 286
Resuscitation-promoting Factors Reveal an Occult Population of Tubercle Bacilli in Sputum
Mukamolova, G. V., Turapov, O., Malkin, J., Woltmann, G., & Barer, M. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200905-0661oc · Cited by 280
Self-citationDorman, S. E., Johnson, J. L., Goldberg, S., Muzanye, G., Padayatchi, N., Bozeman, L., Heilig, C. M., Bernardo, J., Choudhri, S., Grosset, J. H., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200901-0078oc · Cited by 264
McCune, R. M., & Tompsett, R. (1956) · The Journal of Experimental Medicine · doi:10.1084/jem.104.5.737 · Cited by 260
Mouse Model of Necrotic Tuberculosis Granulomas Develops Hypoxic Lesions
Harper, J., Skerry, C., Davis, S. L., Tasneen, R., Weir, M., Kramnik, I., Bishai, W. R., Pomper, M. G., Nuermberger, E. L., & Jain, S. K. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir786 · Cited by 256
Gandotra, S., Schnappinger, D., Monteleone, M., Hillen, W., & Ehrt, S. (2007) · Nature Medicine · doi:10.1038/nm1683 · Cited by 254
Why Is Long-Term Therapy Required to Cure Tuberculosis?
Connolly, L. E., Edelstein, P. H., & Ramakrishnan, L. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040120 · Cited by 229
Stallings, C. L., Stephanou, N. C., Chu, L., Hochschild, A., Nickels, B. E., & Glickman, M. S. (2009) · Cell · doi:10.1016/j.cell.2009.04.041 · Cited by 225
Li, Y., & Zhang, Y. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00052-07 · Cited by 222
Self-citationInhibitors selective for mycobacterial versus human proteasomes
Lin, G., Li, D., de Carvalho, L. P. S., Deng, H., Tao, H., Vogt, G., Wu, K., Schneider, J., Chidawanyika, T., Warren, J. D., et al. (2009) · Nature · doi:10.1038/nature08357 · Cited by 208
Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model
Rosenthal, I. M., Zhang, M., Williams, K. N., Peloquin, C. A., Tyagi, S., Vernon, A. A., Bishai, W. R., Chaisson, R. E., Grosset, J. H., & Nuermberger, E. L. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040344 · Cited by 205
Persistent and dormant tubercle bacilli and latent tuberculosis
Zhang, Y. (2004) · Frontiers in Bioscience · doi:10.2741/1291 · Cited by 195
Self-citationTasneen, R., Li, S.-Y., Peloquin, C. A., Taylor, D., Williams, K. N., Andries, K., Mdluli, K. E., & Nuermberger, E. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05293-11 · Cited by 194
Luidalepp, H., Jõers, A., Kaldalu, N., & Tenson, T. (2011) · Journal of Bacteriology · doi:10.1128/jb.00085-11 · Cited by 188
The Diagnosis and Therapy of Tuberculosis During the Past 100 Years
Mitchison, D. A. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200411-1603oe · Cited by 185
Selective Killing of Nonreplicating Mycobacteria
Bryk, R., Gold, B., Venugopal, A., Singh, J., Samy, R., Pupek, K., Cao, H., Popescu, C., Gurney, M., Hotha, S., et al. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.02.003 · Cited by 182
Hu, Y., Mangan, J. A., Dhillon, J., Sole, K. M., Mitchison, D. A., Butcher, P. D., & Coates, A. R. M. (2000) · Journal of Bacteriology · doi:10.1128/jb.182.22.6358-6365.2000 · Cited by 181
Synergistic Activity of R207910 Combined with Pyrazinamide against Murine Tuberculosis
Ibrahim, M., Andries, K., Lounis, N., Chauffour, A., Truffot-Pernot, C., Jarlier, V., & Veziris, N. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00898-06 · Cited by 175
Singh, R., Barry, C. E., & Boshoff, H. I. (2010) · Journal of Bacteriology · doi:10.1128/jb.01285-09 · Cited by 163
McCune, R. M., Feldmann, F. M., & McDermott, W. (1966) · The Journal of Experimental Medicine · doi:10.1084/jem.123.3.469 · Cited by 157
McDERMOTT, W. (1958) · PubMed Central · Cited by 152
Dhiman, R. K., Mahapatra, S., Slayden, R. A., Boyne, M. E., Lenaerts, A., Hinshaw, J. C., Angala, S. K., Chatterjee, D., Biswas, K., Narayanasamy, P., et al. (2009) · Molecular Microbiology · doi:10.1111/j.1365-2958.2009.06625.x · Cited by 146
Simple Model for Testing Drugs against Nonreplicating Mycobacterium tuberculosis
Sala, C., Dhar, N., Hartkoorn, R. C., Zhang, M., Ha, Y. H., Schneider, P. A., & Cole, S. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00821-10 · Cited by 141
Nitazoxanide Kills Replicating and Nonreplicating Mycobacterium tuberculosis and Evades Resistance
de Carvalho, L. P. S., Lin, G., Jiang, X., & Nathan, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9010719 · Cited by 129
Ma, C., Sim, S., Shi, W., Du, L., Xing, D., & Zhang, Y. (2009) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2009.01857.x · Cited by 129
Self-citationMycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice
Dhar, N., & McKinney, J. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003219107 · Cited by 124
Drug Tolerance in Mycobacterium tuberculosis
Wallis, R. S., Patil, S. A., Cheon, S.-H., Edmonds, K. L., Phillips, M., Perkins, M. D., Joloba, M. L., Namale, A., Johnson, J. L., Teixeira, L., et al. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2600 · Cited by 123
Tasneen, R., Tyagi, S. K., Williams, K. N., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00686-08 · Cited by 101
Effects of persister formation on bacterial response to dosing
Cogan, N. G. (2005) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2005.06.017 · Cited by 91
Gandotra, S., Lebron, M. B., & Ehrt, S. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001040 · Cited by 90
Thibonnier, M., Thiberge, J.-M., & Reuse, H. D. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003810 · Cited by 88
Drusano, G. L., Sgambati, N., Eichas, A., Brown, D. L., Kulawy, R., & Louie, A. (2010) · mBio · doi:10.1128/mbio.00139-10 · Cited by 82
Killing of non-replicating Mycobacterium tuberculosis by 8-hydroxyquinoline
Darby, C. M., & Nathan, C. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq145 · Cited by 79
The DosR regulon of M. tuberculosis and antibacterial tolerance
Bartek, I. L., Rutherford, R. S., Gruppo, V., Morton, R. A., Morris, R. P., Klein, M. R., Visconti, K. C., Ryan, G. J., Schoolnik, G. K., Lenaerts, A. J. M., et al. (2009) · Tuberculosis · doi:10.1016/j.tube.2009.06.001 · Cited by 75
Advances in the Treatment of Tuberculosis
Zhang, Y. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100362 · Cited by 72
Self-citationViable but non-culturable and dormant bacteria: time to resolve an oxymoron and a misnomer?
Barer, M. R. (1997) · Journal of Medical Microbiology · doi:10.1099/00222615-46-8-629 · Cited by 68
Self-citationRifapentine, Moxifloxacin, or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model
Nuermberger, E. L., Tyagi, S. K., Williams, K. N., Rosenthal, I. M., Bishai, W. R., & Grosset, J. H. E. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200507-1047oc · Cited by 67
Resuscitation of Dormant Mycobacterium tuberculosis by Phospholipids or Specific Peptides
Zhang, Y., Yang, Y., Woods, A. S., Cotter, R. J., & Sun, Z. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4993 · Cited by 57
Self-citationPhoY2 but not PhoY1 is the PhoU homologue involved in persisters in Mycobacterium tuberculosis
Shi, W. K., & Zhang, Y. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq103 · Cited by 57
Self-citationByrne, S. T., Gu, P., Zhou, J., Denkin, S. M., Chong, C. R., Sullivan, D. J., Liu, J. O., & Zhang, Y. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00753-07 · Cited by 51
Self-citationThe late emergence of M. tuberculosis in liquid cultures of pulmonary lesions resected from humans.
Hobby, G. L., Auerbach, O., LENERT, T. F., et al. (1954) · PubMed · doi:10.1164/art.1954.70.2.191 · Cited by 49
Emerging drugs for the treatment of tuberculosis
Yew, W. W., Cynamon, M. H., & Zhang, Y. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.521497 · Cited by 25
Self-citation
Cited by
The dormant blood microbiome in chronic, inflammatory diseases
Potgieter, M., Bester, J., Kell, D. B., & Pretorius, E. (2015) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuv013 · Cited by 383
Formation, physiology, ecology, evolution and clinical importance of bacterial persisters
Van den Bergh, B., Fauvart, M., & Michiels, J. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux001 · Cited by 381
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
Zumla, A. I., Gillespie, S. H., Hoelscher, M., Philips, P. P. J., Cole, S. T., Abubakar, I., McHugh, T. D., Schito, M., Maeurer, M., & Nunn, A. J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70328-1 · Cited by 342
Recent updates on drug resistance in Mycobacterium tuberculosis
Singh, R., Dwivedi, S. P., Gaharwar, U. S., Meena, R., Rajamani, P., & Prasad, T. (2020) · Journal of Applied Microbiology · doi:10.1111/jam.14478 · Cited by 337
Bacterial persisters: molecular mechanisms and therapeutic development
Niu, H., Gu, J., & Zhang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01866-5 · Cited by 310
Self-citation
Metadata
- Authors
- Zhang, Y., Yew, W. W., & Barer, M. R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-05
- Volume
- 56
- Issue
- 5
- Pages
- 2223-2230
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2160839923
- Cited by
- 271
- References
- 82
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.